Høberg-Vetti, Hildegunn
Bjorvatn, Cathrine
Fiane, Bent E
Aas, Turid
Woie, Kathrine
Espelid, Helge
Rusken, Tone
Eikesdal, Hans Petter
Listøl, Wenche
Haavind, Marianne T
Knappskog, Per M
Haukanes, Bjørn Ivar
Steen, Vidar M
Hoogerbrugge, Nicoline
Article History
Received: 2 April 2015
Revised: 7 July 2015
Accepted: 4 August 2015
First Online: 9 September 2015
Competing interests
: N Hoogerbrugge is scientific consultant to AstraZeneca since June 2014. HP Eikesdal has received PARP inhibitors free of charge from AbbVie and AstraZeneca for use in clinical trials in patients with breast cancer. The other authors declare no conflict of interest.